Related references
Note: Only part of the references are listed.Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
Ryan B. Corcoran et al.
Oncotarget (2015)
Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
J. Thaddeus Beck et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Ibrutinib and Indolent B-Cell Lymphomas
Akintunde Akinleye et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
Sheridan M. Hoy
DRUGS (2014)
Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases
Sandra W. Cowan-Jacob et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
Andrew J. Brooks et al.
SCIENCE (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands
Arthur Christopoulos et al.
PHARMACOLOGICAL REVIEWS (2014)
IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
J. McDermott et al.
DRUGS OF TODAY (2014)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery
Yinghong Gao et al.
BIOCHEMICAL JOURNAL (2013)
Structure-based discovery of cellular-active allosteric inhibitors of FAK
Naoki Tomita et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling
Corentin Herbert et al.
CANCER CELL (2013)
Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties
Francoise Bono et al.
CANCER CELL (2013)
RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
Matthew Holderfield et al.
CANCER CELL (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Vandetanib for the Treatment of Medullary Thyroid Cancer
Nicole G. Chau et al.
CLINICAL CANCER RESEARCH (2013)
Targeting kinases: a new approach to treating inflammatory rheumatic diseases
David L. Simmons
CURRENT OPINION IN PHARMACOLOGY (2013)
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
Paul Workman et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Trametinib: First Global Approval
Cameron J. M. Wright et al.
DRUGS (2013)
Dabrafenib: First Global Approval
Anita D. Ballantyne et al.
DRUGS (2013)
Trametinib (GSK1120212) in the treatment of melanoma
April K. S. Salama et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
David Viola et al.
FUTURE ONCOLOGY (2013)
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis
Franck E. Nicolini et al.
HAEMATOLOGICA (2013)
DEF Pocket in p38 α Facilitates Substrate Selectivity and Mediates Autophosphorylation
Netanel Tzarum et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Drugs in the United States: Justum Pretium-The Just Price
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Brian I. Rini et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Profiling the kinome: Current capabilities and future challenges
James D. R. Knight et al.
JOURNAL OF PROTEOMICS (2013)
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel et al.
MOLECULAR CANCER (2013)
Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Takashi Ninomiya et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A selective ALK inhibitor in ALK-rearranged patients
James Chih-Hsin Yang
LANCET ONCOLOGY (2013)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou et al.
NATURE (2013)
A public-private partnership to unlock the untargeted kinome
Stefan Knapp et al.
NATURE CHEMICAL BIOLOGY (2013)
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
Sigrun Polier et al.
NATURE CHEMICAL BIOLOGY (2013)
Natural-product-derived fragments for fragment-based ligand discovery
Bjoern Over et al.
NATURE CHEMISTRY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Drugging cancer genomes
Paul Workman et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Gregory T. Kunkel et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Validating therapeutic targets through human genetics
Robert M. Plenge et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
Alastair J. King et al.
PLOS ONE (2013)
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors
Lukasz Skora et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Ivan Angulo et al.
SCIENCE (2013)
Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation
Diane Cibrik et al.
TRANSPLANTATION (2013)
Kinase dysfunction and kinase inhibitors
Cheryl A. London
VETERINARY DERMATOLOGY (2013)
Regorafenib: from bench to bedside in colorectal cancer
Safi Shahda et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2013)
Targeting Diverse Signaling Interaction Sites Allows the Rapid Generation of Bivalent Kinase Inhibitors
Zachary B. Hill et al.
ACS CHEMICAL BIOLOGY (2012)
JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
Adrian Britschgi et al.
CANCER CELL (2012)
Substrate-Selective Inhibition of Protein Kinase PDK1 by Small Compounds that Bind to the PIF-Pocket Allosteric Docking Site
Katrien Busschots et al.
CHEMISTRY & BIOLOGY (2012)
Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation
Ian P. Salt et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders
Tadeusz Robak et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Targeting the PI3K signaling pathway in cancer therapy
Chandra Bartholomeusz et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Jeremy S. Logue et al.
GENES & DEVELOPMENT (2012)
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications
M. Sanchez-Martin et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Omics and therapy - A basis for precision medicine
Joseph P. Garay et al.
MOLECULAR ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Chipping away at the lung cancer genome
William Pao et al.
NATURE MEDICINE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Modular evolution of phosphorylation-based signalling systems
Jing Jin et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt
Kui Lin et al.
SCIENCE SIGNALING (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Rita Andraos et al.
CANCER DISCOVERY (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Livio Trusolino et al.
CANCER DISCOVERY (2012)
Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases
Kenneth M. Comess et al.
ACS CHEMICAL BIOLOGY (2011)
Discovery of selective irreversible inhibitors for EGFR-T790M
Wenjun Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
A Blueprint for Advancing Genetics-Based Cancer Therapy
William R. Sellers
CELL (2011)
The secret life of kinases: functions beyond catalysis
Jens Rauch et al.
CELL COMMUNICATION AND SIGNALING (2011)
Allosteric Regulation of Protein Kinase PKCζ by the N-Terminal C1 Domain and Small Compounds to the PIF-Pocket
Laura A. Lopez-Garcia et al.
CHEMISTRY & BIOLOGY (2011)
In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Matthew P. Patricelli et al.
CHEMISTRY & BIOLOGY (2011)
Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site
Jingsong Yang et al.
CHEMISTRY & BIOLOGY (2011)
Targeting Energy Metabolic and Oncogenic Signaling Pathways in Triple-negative Breast Cancer by a Novel Adenosine Monophosphate-activated Protein Kinase (AMPK) Activator
Kuen-Haur Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Natalia Jura et al.
MOLECULAR CELL (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Crizotinib
Alice T. Shaw et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Turning a protein kinase on or off from a single allosteric site via disulfide trapping
Jack D. Sadowsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Protein kinases: evolution of dynamic regulatory proteins
Susan S. Taylor et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors
Hiu-yan Chan et al.
ADVANCES IN THERAPY (2010)
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Doriano Fabbro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Targeting kinases for the treatment of inflammatory diseases
Susanne Mueller et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data
Xinan Yang et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2010)
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Stephen M. Massa et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Through the Gatekeeper Door: Exploiting the Active Kinase Conformation
Fabio Zuccotto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay
Wolfgang Jahnke et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
The (un)targeted cancer kinome
Oleg Fedorov et al.
NATURE CHEMICAL BIOLOGY (2010)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Kinase mutations in human disease: interpreting genotype-phenotype relationships
Piya Lahiry et al.
NATURE REVIEWS GENETICS (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice
Maxime Cazorla et al.
PLOS ONE (2010)
Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?
Hui Cheng et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
Allosteric Protein Kinase Regulation by Pseudokinases: Insights from STRAD
Thanashan Rajakulendran et al.
SCIENCE SIGNALING (2010)
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
Terence O'Reilly et al.
TRANSLATIONAL ONCOLOGY (2010)
Allosteric IGF-1R Inhibitors
Timo Heinrich et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Characterization of the CHK1 Allosteric Inhibitor Binding Site
Darin Vanderpool et al.
BIOCHEMISTRY (2009)
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
Antonella Converso et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?
Haile Tecle et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Structural biology contributions to tyrosine kinase drug discovery
Sandra W. Cowan-Jacob et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Enhancing mTOR-targeted cancer therapy
Xuerong Wang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1
Valerie Hindie et al.
NATURE CHEMICAL BIOLOGY (2009)
Inhibitor hijacking of Akt activation
Tatsuya Okuzumi et al.
NATURE CHEMICAL BIOLOGY (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting protein kinases in central nervous system disorders
Laura K. Chico et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Structure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation
Elton Zeqiraj et al.
SCIENCE (2009)
Cell Signaling in Space and Time: Where Proteins Come Together and When They're Apart
John D. Scott et al.
SCIENCE (2009)
Is resistance useless? Multidrug resistance and collateral sensitivity
Matthew D. Hall et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Structural coupling of SH2-kinase domains links fes and Abl substrate recognition and kinase activation
Panagis Filippakopoulos et al.
CELL (2008)
Rethinking pseudokinases
Natarajan Kannan et al.
CELL (2008)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies
Yong Jia et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
The challenge of selecting protein kinase assays for lead discovery optimization
Haiching Ma et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase
Brian K. Albrecht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
A peptoid Antibody surrogate that antagonizes VEGF receptor 2 activity
D. Gomika Udugamasooriya et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
High-throughput kinase profiling as a platform for drug discovery
David M. Goldstein et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
TGFβ-SMAD signal transduction:: molecular specificity and functional flexibility
Bernhard Schmierer et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family
Matthew J. Sanders et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST)
Safdar Ali et al.
GENE (2007)
Flying under the radar:: the new wave of BCR-ABL inhibitors
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Targeting HER proteins in cancer therapy and the role of the non-target HER3
A. C. Hsieh et al.
BRITISH JOURNAL OF CANCER (2007)
Mechanisms of specificity in protein phosphorylation (vol 8, pg 530, 2007)
Jeffrey A. Ubersax et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Mechanisms of specificity in protein phosphorylation
Jeffrey A. Ubersax et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Classical PKC isoforms in cancer
Georg Martiny-Baron et al.
PHARMACOLOGICAL RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors
Zhi-Fu Tao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
A clickable inhibitor reveals context-dependent autoactivation of p90 RSK
Michael S. Cohen et al.
NATURE CHEMICAL BIOLOGY (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Structural and functional diversity of the microbial kinome
Natarajan Kannan et al.
PLOS BIOLOGY (2007)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
Fragments, network biology and designing multiple ligands
Richard Morphy et al.
DRUG DISCOVERY TODAY (2007)
KIT mutations in GIST
Jonathan A. Fletcher et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Functional interrogation of the kinome using nucleotide acyl phosphates
Matthew P. Patricelli et al.
BIOCHEMISTRY (2007)
Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
Allan Wissner et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Emerging drugs for non-small-cell lung cancer
Enriqueta Felip et al.
EXPERT OPINION ON EMERGING DRUGS (2007)
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth et al.
CURRENT OPINION IN ONCOLOGY (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
Christian Rommel et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Structural biology of protein tyrosine kinases
S. W. Cowan-Jacob
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
Brian P. Rubin et al.
LABORATORY INVESTIGATION (2006)
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer
John V. Heymach et al.
CLINICAL CANCER RESEARCH (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
Robert J. Motzer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
An efficient rapid system for profiling the cellular activities of molecular libraries
JS Melnick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
Alejandro Wolf-Yadlin et al.
MOLECULAR SYSTEMS BIOLOGY (2006)
Emerging roles of pseudokinases
Jerome Boudeau et al.
TRENDS IN CELL BIOLOGY (2006)
Patterns of pulmonary complications associated with sirolimus
Prashant N. Chhajed et al.
RESPIRATION (2006)
Small molecule glucokinase activators as glucose lowering agents: A new paradigm for diabetes therapy
Kevin R. Guertin et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Dynamics of signaling by PKA
SS Taylor et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Kinomics: Characterizing the therapeutically validated kinase space
M Vieth et al.
DRUG DISCOVERY TODAY (2005)
Features of selective kinase inhibitors
ZA Knight et al.
CHEMISTRY & BIOLOGY (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy
HX Chen et al.
ANALYTICAL BIOCHEMISTRY (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
CW Lindsley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
SF Barnett et al.
BIOCHEMICAL JOURNAL (2005)
Protein posttranslational modifications: The chemistry of proteome diversifications
CT Walsh et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
Kinomics-structural biology and chemogenomics of kinase inhibitors and targets
M Vieth et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
J Cools et al.
CANCER RESEARCH (2004)
Regulation of protein kinases: Controlling activity through activation segment conformation
B Nolen et al.
MOLECULAR CELL (2004)
Opinion - Switching on kinases: oncogenic activation of BRAF and the PDGFR family
NJ Dibb et al.
NATURE REVIEWS CANCER (2004)
Creating chemical diversity to target protein kinases
B Li et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
JF Ohren et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
Strategies to overcome resistance to targeted protein kinase inhibitors
H Daub et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
R Perez-Soler
CLINICAL CANCER RESEARCH (2004)
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer
F Carlomagno et al.
JOURNAL OF CHEMOTHERAPY (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors
S Blencke et al.
CHEMISTRY & BIOLOGY (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice
KW McIntyre et al.
ARTHRITIS AND RHEUMATISM (2003)
Mutational analysis of the tyrosine kinome in colorectal cancers
A Bardelli et al.
SCIENCE (2003)
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
J Cools et al.
CANCER CELL (2003)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
Archaeal protein kinases and protein phosphatases: insights from genomics and biochemistry
PJ Kennelly
BIOCHEMICAL JOURNAL (2003)
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines
MD Gaul et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
A putative molecular-activation switch in the transmembrane domain of erbB2
SJ Fleishman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Regulation of insulin receptor function by a small molecule insulin receptor activator
C Pender et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
C Pargellis et al.
NATURE STRUCTURAL BIOLOGY (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
D Fabbro et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Design and discovery of small molecules targeting Raf-1 kinase
TB Lowinger et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Tyrosine kinase inhibitors: From rational design to clinical trials
P Traxler et al.
MEDICINAL RESEARCH REVIEWS (2001)
Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells
M Li et al.
DIABETES (2001)
The role of protein phosphorylation in human health and disease - Delivered on June 30th 2001 at the FEBS Meeting in Lisbon
P Cohen
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
AJ Barker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Specificity and mechanism of action of some commonly used protein kinase inhibitors
SP Davies et al.
BIOCHEMICAL JOURNAL (2000)
Share Paper
